Floatz logo

Empegfilgrastim

Myelosuppression, Non-Human Animal

Moscow Clinical Scientific Centerprotein_peptideUnknownDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Myelosuppression, Non-Human Animal cohort.

Asset / SponsorPhaseRating
Trilaciclib
The First Affiliated Hospital of Xiamen University
Phase 2B
Docetaxel
The First Affiliated Hospital of Xiamen University
Phase 2B
Myelo001
Myelo Therapeutics GmbH
Phase 2B
Sacituzumab Tirumotecan
The First Affiliated Hospital of Xiamen University
Phase 2CCC
Sulanemadlin
Aileron Therapeutics, Inc.
Phase 1CC

Same molecule, other indications

Empegfilgrastim is also rated in:

cancerDormant
D
Indicative · Unknown
30 / 100
View asset →
digestive system cancerDormant
D
Indicative · Unknown
30 / 100
View asset →
female reproductive system neoplasmDormant
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →